Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ended
Participants planned
48
Countries
1
Sites
1
Healthy volunteers
Key facts
- Sponsor
- Laboratorios Normon S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Not possible to specify
- Trial duration
- 19 Nov 2024 → 22 Jan 2025
- Decision date (initial)
- 2024-09-09
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Healthy volunteers
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Laboratorios Normon S.A.
- Sponsor organisation
- Laboratorios Normon S.A.
- Address
- Ronda De Valdecarrizo 6
- City
- Tres Cantos
- Postcode
- 28760
- Country
- Spain
Scientific contact point
- Organisation
- Laboratorios Normon S.A.
- Contact name
- Carlos Govantes (R&D Director)
Public contact point
- Organisation
- Laboratorios Normon S.A.
- Contact name
- Carlos Govantes (R&D Director)
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Spain | Ended | 48 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Spain | 2024-11-19 | 2025-01-22 | 2024-11-20 | 2024-12-04 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-08-01 | Spain | Acceptable 2024-09-09
|
2024-09-09 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2024-09-18 | Spain | Acceptable 2024-10-25
|
2024-10-25 |